Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer

Next Previous
Trial Profile

An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Folitixorin (Primary) ; Bevacizumab; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Isofol Medical

Most Recent Events

  • 17 Jan 2021 Results (n=81) evalauting biomarkers of arfolitixorin/5-FU-based treatment in relation to safety and response in metastatic colorectal cancer, presented at the 2021 Gastrointestinal Cancers Symposium
  • 15 Jan 2021 According to an Isofol Medical media release, gene expression results from the study will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) 2021.
  • 30 Sep 2020 Results (n=31) from the extension cohort are presented in an Isofol Medical media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top